ABU DHABI/WAM AD Ports Group, a leading enabler of global trade, logistics, and industry, today ...
Read More »Concordia on the wrong side of pharma history
Max Nisen Disappointing earnings. Substantially lower guidance for 2016. A CFO departure. A suspended dividend. A drug-pricing controversy. Oh, and a libel suit against a chicken farmer. All were features of Concordia International’s unusually calamitous earnings report on Friday. For a day, at least, the Ontario-based specialty pharma firm one-upped its better-known progenitor Valeant, which has had a mixed ...
Read More »